InMed Adds Skin Disorder Treatment to Pipeline

InMed Pharmaceuticals Inc. (CSE:IN,OTCQB:IMLFF) announced that it has added INM-750, a new therapy, to its pipeline. INM-750 is used to treat epidermolysis bullosa simplex, a rare, genetically inherited skin disorder.

As quoted in the press release:

INM-750 is designed to suppress pathological skin growth, differentiation and inflammation that are signature characteristics of EBS.

InMed anticipates commencing pre-clinical studies of INM-750 in February, 2015 with initial data expected by Q2 2015. The initiation of INM-750 signals InMed’s entry into the dermatological market and adds to the Company’s rapidly advancing pipeline of cannabis-based therapeutics, which includes CTI-805 for glaucoma and CT-091 for arthritis, both of which are expected to enter human clinical studies in 2015.

Craig Schneider, president and CEO of InMed, commented:

We are pleased to continue the strategic diversification of our pipeline by adding a third therapy identified by our proprietary platform technology. The discovery of INM-750 furthers our corporate strategy of developing therapies for diseases that may be approved for Orphan drug designation.

Click here to read the full InMed Pharmaceuticals Inc. (CSE:IN,OTCQB:IMLFF) press release.